Key Drivers
- Liquidity cushion
- Rising leverage
- Negative cash flow
AIAI Summary
ZYME is shifting from a purely binary clinical-stage biotech to a more durable, cash-supported hybrid if the Theravance deal closes, but the investment still hinges on the upcoming zanidatamab FDA decision while rising leverage and persistent cash burn keep execution risk high.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity cushion
- •Rising leverage
- •Negative cash flow
ZYME has strong near-term liquidity, but rapidly rising leverage, persistent losses, negative cash flow, and a rich valuation make the stock look financially stretched.
Price Behavior
Key Price Behavior Insights:
- •Base holding
- •Higher lows
- •Near resistance
Over the last month, ZYME has shifted from choppy action into a short-term uptrend after repeatedly holding the $23.1–$23.3 base, but it must break and hold above $26.31 to confirm the rally.
Sharp rebound from $24.35 to $26.31 after mid-June support held, raising short-term pullback risk
Sentiment & News
Key News Insights:
- •Portfolio shift
- •Cash-flow boost
- •Pipeline progress
Zymeworks is pivoting toward a hybrid biotech-plus-royalty model via its $929 million all-cash Theravance buyout while still advancing pipeline and clinical programs. #M&A
The acquisition should materially reshape Zymeworks' business mix and may support longer-term stability, though execution risk remains as it balances integration with ongoing R&D
Similar Companies in Healthcare
Other companies in the same sector with AI ratings